rite3-platform
(2)
SEED Therapeutics
SEED Therapeutics is a clinical-stage biotechnology company pioneering rationally designed molecular glue degraders to treat diseases driven by proteins long considered undruggable. Powered by its proprietary RITE3 discovery platform - which pairs disease-causing target proteins with the most suitable of more than 600 human E3 ligases - SEED reprograms the cell's own ubiquitin-proteasome system to destroy harmful proteins rather than merely block them. Founded in 2020 by CEO Lan Huang and a group of protein-degradation pioneers including Nobel laureate Avram Hershko, the company advanced its lead oral RBM39 degrader ST-01156 into first-in-human Phase 1 trials in early 2026, with a broader pipeline spanning oncology, neurodegeneration, immunology and virology backed by partners Eli Lilly and Eisai.
Lan Huang
Lan Huang is a chemist turned biotech entrepreneur and the Co-Founder, Chairman and CEO of SEED Therapeutics, a New York clinical-stage company designing molecular glues that direct the cell's own disposal machinery to break down disease-driving proteins once considered undruggable. She earlier founded BeyondSpring Pharmaceuticals and took it public on NASDAQ. A UC Berkeley PhD who solved an early E3 ubiquitin ligase structure, she built SEED around targeted protein degradation with collaborators including Nobel laureate Avram Hershko, and secured partnerships with Eli Lilly and Eisai.